{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=47",
    "query": {
      "intervention": "Intermediate dose",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 2636,
    "total_pages": 264,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T12:37:17.650Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01662908",
      "title": "A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Deep Vein Thrombosis",
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "edoxaban tosylate",
          "type": "DRUG"
        },
        {
          "name": "enoxaparin/unfractionated heparin",
          "type": "DRUG"
        },
        {
          "name": "warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2012-08",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 29,
      "location_summary": "Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01662908"
    },
    {
      "nct_id": "NCT03017508",
      "title": "Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Social Anxiety Disorder",
        "Performance Anxiety"
      ],
      "interventions": [
        {
          "name": "BHV-0223",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2017-01",
      "completion_date": "2021-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-05-20",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03017508"
    },
    {
      "nct_id": "NCT04282174",
      "title": "CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Hematologic Malignancy",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CliniMACS",
          "type": "DEVICE"
        },
        {
          "name": "Bone Marrow Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Hyperfractionated Total Body Irradiation",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "Up to 74 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04282174"
    },
    {
      "nct_id": "NCT00993135",
      "title": "Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia",
        "Renal Toxicity"
      ],
      "interventions": [
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00993135"
    },
    {
      "nct_id": "NCT07676435",
      "title": "Ongoing Lung Decline With Age Intensified Response",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Lung Function Decline"
      ],
      "interventions": [
        {
          "name": "Fisetin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-06-17",
      "completion_date": "2027-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07676435"
    },
    {
      "nct_id": "NCT01455740",
      "title": "A Commitment Device for Medication Adherence Among HIV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acquired Immunodeficiency Syndrome",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Provider Visit Incentive (PVI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Incentive Choice (IC)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Bureau of Economic Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2011-10",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2017-12-18",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01455740"
    },
    {
      "nct_id": "NCT07104318",
      "title": "Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Helicobacter Pylori"
      ],
      "interventions": [
        {
          "name": "Bismuth quadruple therapy with optimized proton pump inhibitor (PPI)",
          "type": "DRUG"
        },
        {
          "name": "Bismuth quadruple therapy with standard proton pump inhibitor (PPI)",
          "type": "DRUG"
        },
        {
          "name": "Clarithromycin triple therapy with optimized proton pump inhibitor (PPI)",
          "type": "DRUG"
        },
        {
          "name": "Clarithromycin triple therapy with standard PPI",
          "type": "DRUG"
        },
        {
          "name": "Standard bismuth quadruple therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2027-01-01",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07104318"
    },
    {
      "nct_id": "NCT02649790",
      "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)",
        "Metastatic Colorectal Cancer (mCRC)",
        "Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
        "Higher-Risk Myelodysplastic Syndrome (HR-MDS)",
        "Acute Myeloid Leukemia (AML)",
        "Newly Diagnosed Intermediate/High-Risk MDS"
      ],
      "interventions": [
        {
          "name": "KPT-8602",
          "type": "DRUG"
        },
        {
          "name": "ASTX727",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2016-01",
      "completion_date": "2024-12-23",
      "has_results": false,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02649790"
    },
    {
      "nct_id": "NCT02597478",
      "title": "Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Fentanyl Sublingual Spray",
          "type": "DRUG"
        },
        {
          "name": "Shuttle Walk Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mental Ability Tests",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Phone Call",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2016-01-04",
      "completion_date": "2021-01-27",
      "has_results": true,
      "last_update_posted_date": "2021-02-09",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02597478"
    },
    {
      "nct_id": "NCT04701918",
      "title": "Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Urothelial Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cryoablation",
          "type": "PROCEDURE"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2021-06-04",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-30T12:37:17.650Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701918"
    }
  ]
}